Selected research
Industry Research
Benign Prostatic Hypertrophy Medication Industry Research Report 2026
Market perspective
The global Benign Prostatic Hypertrophy Medication market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Benign Prostatic Hypertrophy Medication is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Benign Prostatic Hypertrophy Medication is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Benign Prostatic Hypertrophy Medication is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Benign Prostatic Hypertrophy Medication include Abbott Laboratories, Allergan, Inc, Astellas, Kissei Pharmaceutical, Merck & Co., Sanofi, Hainan Selike Pharmaceutical Co., Ltd., Hunan Shentaichun Pharmaceutical Co., Ltd. and China Resources Saike Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Benign Prostatic Hypertrophy Medication market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Benign Prostatic Hypertrophy Medication Market by Company
Abbott Laboratories
Allergan, Inc
Astellas
Kissei Pharmaceutical
Merck & Co.
Sanofi
Hainan Selike Pharmaceutical Co., Ltd.
Hunan Shentaichun Pharmaceutical Co., Ltd.
China Resources Saike Pharmaceutical Co., Ltd.
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Jiangsu Yongan Pharmaceutical Co., Ltd.
Kunming Jida Pharmaceutical Co., Ltd.
Lunan Beite Pharmaceutical Co., Ltd.
Nanjing Meirui Pharmaceutical Co., Ltd.
Shandong Langnuo Pharmaceutical Co., Ltd.
Shanghai Modern Pharmaceutical Co., Ltd.
Shanghai Abbott Pharmaceutical Co., Ltd.
Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
Suzhou Dongrui Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical Co., Ltd.
Zhongshan Kekekang Pharmaceutical Co., Ltd.
Benign Prostatic Hypertrophy Medication Segment by Type
Terazosin
Tamsulosin
Silodosin
Prusatide
Finasteride
Aprilite
Alfuzosin
Benign Prostatic Hypertrophy Medication Segment by Application
Hospital
Clinic
Other
Benign Prostatic Hypertrophy Medication Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Benign Prostatic Hypertrophy Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Benign Prostatic Hypertrophy Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Benign Prostatic Hypertrophy Medication.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Benign Prostatic Hypertrophy Medication manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Benign Prostatic Hypertrophy Medication by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Benign Prostatic Hypertrophy Medication in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Benign Prostatic Hypertrophy Medication Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Benign Prostatic Hypertrophy Medication Sales (K Units) of Manufacturers (2021-2026)
Table 7. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Benign Prostatic Hypertrophy Medication Revenue of Manufacturers (2021-2026)
Table 9. Global Benign Prostatic Hypertrophy Medication Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Benign Prostatic Hypertrophy Medication Average Price (US$/Unit) of Manufacturers (2021-2026)
Table 11. Global Benign Prostatic Hypertrophy Medication Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Benign Prostatic Hypertrophy Medication, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Benign Prostatic Hypertrophy Medication, Product Type & Application
Table 14. Global Benign Prostatic Hypertrophy Medication Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Benign Prostatic Hypertrophy Medication by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Abbott Laboratories Company Information
Table 19. Abbott Laboratories Business Overview
Table 20. Abbott Laboratories Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 21. Abbott Laboratories Benign Prostatic Hypertrophy Medication Product Portfolio
Table 22. Abbott Laboratories Recent Developments
Table 23. Allergan, Inc Company Information
Table 24. Allergan, Inc Business Overview
Table 25. Allergan, Inc Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 26. Allergan, Inc Benign Prostatic Hypertrophy Medication Product Portfolio
Table 27. Allergan, Inc Recent Developments
Table 28. Astellas Company Information
Table 29. Astellas Business Overview
Table 30. Astellas Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 31. Astellas Benign Prostatic Hypertrophy Medication Product Portfolio
Table 32. Astellas Recent Developments
Table 33. Kissei Pharmaceutical Company Information
Table 34. Kissei Pharmaceutical Business Overview
Table 35. Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 36. Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Product Portfolio
Table 37. Kissei Pharmaceutical Recent Developments
Table 38. Merck & Co. Company Information
Table 39. Merck & Co. Business Overview
Table 40. Merck & Co. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 41. Merck & Co. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 42. Merck & Co. Recent Developments
Table 43. Sanofi Company Information
Table 44. Sanofi Business Overview
Table 45. Sanofi Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 46. Sanofi Benign Prostatic Hypertrophy Medication Product Portfolio
Table 47. Sanofi Recent Developments
Table 48. Hainan Selike Pharmaceutical Co., Ltd. Company Information
Table 49. Hainan Selike Pharmaceutical Co., Ltd. Business Overview
Table 50. Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 51. Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 52. Hainan Selike Pharmaceutical Co., Ltd. Recent Developments
Table 53. Hunan Shentaichun Pharmaceutical Co., Ltd. Company Information
Table 54. Hunan Shentaichun Pharmaceutical Co., Ltd. Business Overview
Table 55. Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 56. Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 57. Hunan Shentaichun Pharmaceutical Co., Ltd. Recent Developments
Table 58. China Resources Saike Pharmaceutical Co., Ltd. Company Information
Table 59. China Resources Saike Pharmaceutical Co., Ltd. Business Overview
Table 60. China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 61. China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 62. China Resources Saike Pharmaceutical Co., Ltd. Recent Developments
Table 63. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Company Information
Table 64. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Business Overview
Table 65. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 67. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Recent Developments
Table 68. Jiangsu Yongan Pharmaceutical Co., Ltd. Company Information
Table 69. Jiangsu Yongan Pharmaceutical Co., Ltd. Business Overview
Table 70. Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 72. Jiangsu Yongan Pharmaceutical Co., Ltd. Recent Developments
Table 73. Kunming Jida Pharmaceutical Co., Ltd. Company Information
Table 74. Kunming Jida Pharmaceutical Co., Ltd. Business Overview
Table 75. Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 77. Kunming Jida Pharmaceutical Co., Ltd. Recent Developments
Table 78. Lunan Beite Pharmaceutical Co., Ltd. Company Information
Table 79. Lunan Beite Pharmaceutical Co., Ltd. Business Overview
Table 80. Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 82. Lunan Beite Pharmaceutical Co., Ltd. Recent Developments
Table 83. Nanjing Meirui Pharmaceutical Co., Ltd. Company Information
Table 84. Nanjing Meirui Pharmaceutical Co., Ltd. Business Overview
Table 85. Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 87. Nanjing Meirui Pharmaceutical Co., Ltd. Recent Developments
Table 88. Shandong Langnuo Pharmaceutical Co., Ltd. Company Information
Table 89. Shandong Langnuo Pharmaceutical Co., Ltd. Business Overview
Table 90. Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 92. Shandong Langnuo Pharmaceutical Co., Ltd. Recent Developments
Table 93. Shanghai Modern Pharmaceutical Co., Ltd. Company Information
Table 94. Shanghai Modern Pharmaceutical Co., Ltd. Business Overview
Table 95. Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 97. Shanghai Modern Pharmaceutical Co., Ltd. Recent Developments
Table 98. Shanghai Abbott Pharmaceutical Co., Ltd. Company Information
Table 99. Shanghai Abbott Pharmaceutical Co., Ltd. Business Overview
Table 100. Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 102. Shanghai Abbott Pharmaceutical Co., Ltd. Recent Developments
Table 103. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Company Information
Table 104. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Business Overview
Table 105. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 107. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Recent Developments
Table 108. Suzhou Dongrui Pharmaceutical Co., Ltd. Company Information
Table 109. Suzhou Dongrui Pharmaceutical Co., Ltd. Business Overview
Table 110. Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 112. Suzhou Dongrui Pharmaceutical Co., Ltd. Recent Developments
Table 113. Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
Table 114. Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
Table 115. Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 117. Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
Table 118. Zhongshan Kekekang Pharmaceutical Co., Ltd. Company Information
Table 119. Zhongshan Kekekang Pharmaceutical Co., Ltd. Business Overview
Table 120. Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 122. Zhongshan Kekekang Pharmaceutical Co., Ltd. Recent Developments
Table 123. Global Benign Prostatic Hypertrophy Medication Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 124. Global Benign Prostatic Hypertrophy Medication Sales by Region (2021-2026) & (K Units)
Table 125. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Region (2021-2026)
Table 126. Global Benign Prostatic Hypertrophy Medication Sales by Region (2027-2032) & (K Units)
Table 127. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Region (2027-2032)
Table 128. Global Benign Prostatic Hypertrophy Medication Revenue by Region (2021-2026) & (US$ Million)
Table 129. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Region (2021-2026)
Table 130. Global Benign Prostatic Hypertrophy Medication Revenue by Region (2027-2032) & (US$ Million)
Table 131. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Region (2027-2032)
Table 132. North America Benign Prostatic Hypertrophy Medication Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 133. North America Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026) & (K Units)
Table 134. North America Benign Prostatic Hypertrophy Medication Sales by Country (2027-2032) & (K Units)
Table 135. North America Benign Prostatic Hypertrophy Medication Revenue by Country (2021-2026) & (US$ Million)
Table 136. North America Benign Prostatic Hypertrophy Medication Revenue by Country (2027-2032) & (US$ Million)
Table 137. Europe Benign Prostatic Hypertrophy Medication Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 138. Europe Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026) & (K Units)
Table 139. Europe Benign Prostatic Hypertrophy Medication Sales by Country (2027-2032) & (K Units)
Table 140. Europe Benign Prostatic Hypertrophy Medication Revenue by Country (2021-2026) & (US$ Million)
Table 141. Europe Benign Prostatic Hypertrophy Medication Revenue by Country (2027-2032) & (US$ Million)
Table 142. Asia Pacific Benign Prostatic Hypertrophy Medication Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 143. Asia Pacific Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026) & (K Units)
Table 144. Asia Pacific Benign Prostatic Hypertrophy Medication Sales by Country (2027-2032) & (K Units)
Table 145. Asia Pacific Benign Prostatic Hypertrophy Medication Revenue by Country (2021-2026) & (US$ Million)
Table 146. Asia Pacific Benign Prostatic Hypertrophy Medication Revenue by Country (2027-2032) & (US$ Million)
Table 147. South America Benign Prostatic Hypertrophy Medication Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 148. South America Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026) & (K Units)
Table 149. South America Benign Prostatic Hypertrophy Medication Sales by Country (2027-2032) & (K Units)
Table 150. South America Benign Prostatic Hypertrophy Medication Revenue by Country (2021-2026) & (US$ Million)
Table 151. South America Benign Prostatic Hypertrophy Medication Revenue by Country (2027-2032) & (US$ Million)
Table 152. Middle East and Africa Benign Prostatic Hypertrophy Medication Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 153. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026) & (K Units)
Table 154. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales by Country (2027-2032) & (K Units)
Table 155. Middle East and Africa Benign Prostatic Hypertrophy Medication Revenue by Country (2021-2026) & (US$ Million)
Table 156. Middle East and Africa Benign Prostatic Hypertrophy Medication Revenue by Country (2027-2032) & (US$ Million)
Table 157. Global Benign Prostatic Hypertrophy Medication Sales by Type (2021-2026) & (K Units)
Table 158. Global Benign Prostatic Hypertrophy Medication Sales by Type (2027-2032) & (K Units)
Table 159. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Type (2021-2026)
Table 160. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Type (2027-2032)
Table 161. Global Benign Prostatic Hypertrophy Medication Revenue by Type (2021-2026) & (US$ Million)
Table 162. Global Benign Prostatic Hypertrophy Medication Revenue by Type (2027-2032) & (US$ Million)
Table 163. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Type (2021-2026)
Table 164. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Type (2027-2032)
Table 165. Global Benign Prostatic Hypertrophy Medication Price by Type (2021-2026) & (US$/Unit)
Table 166. Global Benign Prostatic Hypertrophy Medication Price by Type (2027-2032) & (US$/Unit)
Table 167. Global Benign Prostatic Hypertrophy Medication Sales by Application (2021-2026) & (K Units)
Table 168. Global Benign Prostatic Hypertrophy Medication Sales by Application (2027-2032) & (K Units)
Table 169. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2021-2026)
Table 170. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2027-2032)
Table 171. Global Benign Prostatic Hypertrophy Medication Revenue by Application (2021-2026) & (US$ Million)
Table 172. Global Benign Prostatic Hypertrophy Medication Revenue by Application (2027-2032) & (US$ Million)
Table 173. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Application (2021-2026)
Table 174. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Application (2027-2032)
Table 175. Global Benign Prostatic Hypertrophy Medication Price by Application (2021-2026) & (US$/Unit)
Table 176. Global Benign Prostatic Hypertrophy Medication Price by Application (2027-2032) & (US$/Unit)
Table 177. Key Raw Materials
Table 178. Raw Materials Key Suppliers
Table 179. Benign Prostatic Hypertrophy Medication Distributors List
Table 180. Benign Prostatic Hypertrophy Medication Customers List
Table 181. Benign Prostatic Hypertrophy Medication Industry Trends
Table 182. Benign Prostatic Hypertrophy Medication Industry Drivers
Table 183. Benign Prostatic Hypertrophy Medication Industry Restraints
Table 184. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Benign Prostatic Hypertrophy Medication Product Image
Figure 5. Global Benign Prostatic Hypertrophy Medication Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Benign Prostatic Hypertrophy Medication Market Size (2021-2032) & (US$ Million)
Figure 7. Global Benign Prostatic Hypertrophy Medication Sales (2021-2032) & (K Units)
Figure 8. Global Benign Prostatic Hypertrophy Medication Average Price (US$/Unit) & (2021-2032)
Figure 9. Terazosin Product Image
Figure 10. Tamsulosin Product Image
Figure 11. Silodosin Product Image
Figure 12. Prusatide Product Image
Figure 13. Finasteride Product Image
Figure 14. Aprilite Product Image
Figure 15. Alfuzosin Product Image
Figure 16. Hospital Product Image
Figure 17. Clinic Product Image
Figure 18. Other Product Image
Figure 19. Global Benign Prostatic Hypertrophy Medication Revenue Share by Manufacturers in 2025
Figure 20. Global Manufacturers of Benign Prostatic Hypertrophy Medication, Manufacturing Sites & Headquarters
Figure 21. Global Top 5 and 10 Benign Prostatic Hypertrophy Medication Players Market Share by Revenue in 2025
Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 23. Global Benign Prostatic Hypertrophy Medication Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 24. Global Benign Prostatic Hypertrophy Medication Sales by Region in 2025
Figure 25. Global Benign Prostatic Hypertrophy Medication Revenue by Region in 2025
Figure 26. North America Benign Prostatic Hypertrophy Medication Market Size by Country in 2025
Figure 27. North America Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2021-2032)
Figure 28. North America Benign Prostatic Hypertrophy Medication Revenue Market Share by Country (2021-2032)
Figure 29. United States Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 30. Canada Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 31. Mexico Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 32. Europe Benign Prostatic Hypertrophy Medication Market Size by Country in 2025
Figure 33. Europe Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2021-2032)
Figure 34. Europe Benign Prostatic Hypertrophy Medication Revenue Market Share by Country (2021-2032)
Figure 35. Germany Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 36. France Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 37. U.K. Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 38. Italy Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 39. Russia Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 40. Spain Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. Netherlands Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 42. Switzerland Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 43. Sweden Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 44. Poland Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 45. Asia Pacific Benign Prostatic Hypertrophy Medication Market Size by Country in 2025
Figure 46. Asia Pacific Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2021-2032)
Figure 47. Asia Pacific Benign Prostatic Hypertrophy Medication Revenue Market Share by Country (2021-2032)
Figure 48. China Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 49. Japan Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 50. South Korea Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 51. India Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 52. Australia Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 53. Taiwan Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 54. Southeast Asia Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 55. Southeast Asia Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 56. South America Benign Prostatic Hypertrophy Medication Market Size by Country in 2025
Figure 57. South America Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2021-2032)
Figure 58. South America Benign Prostatic Hypertrophy Medication Revenue Market Share by Country (2021-2032)
Figure 59. Brazil Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 60. Argentina Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 61. Chile Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 62. Middle East and Africa Benign Prostatic Hypertrophy Medication Market Size by Country in 2025
Figure 63. Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2021-2032)
Figure 64. Middle East and Africa Benign Prostatic Hypertrophy Medication Revenue Market Share by Country (2021-2032)
Figure 65. Egypt Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 66. South Africa Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 67. Israel Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 68. Türkiye Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 69. GCC Countries Benign Prostatic Hypertrophy Medication Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 70. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Type (2021-2032)
Figure 71. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Type (2021-2032)
Figure 72. Global Benign Prostatic Hypertrophy Medication Price (US$/Unit) by Type (2021-2032)
Figure 73. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2021-2032)
Figure 74. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Application (2021-2032)
Figure 75. Global Benign Prostatic Hypertrophy Medication Price (US$/Unit) by Application (2021-2032)
Figure 76. Benign Prostatic Hypertrophy Medication Value Chain
Figure 77. Benign Prostatic Hypertrophy Medication Production Mode & Process
Figure 78. Direct Comparison with Distribution Share
Figure 79. Distributors Profiles
Figure 80. Benign Prostatic Hypertrophy Medication Industry Opportunities and Challenges
Scope & coverage.
Types
- Terazosin
- Tamsulosin
- Silodosin
- Prusatide
- Finasteride
- Aprilite
- Alfuzosin
Applications
- Hospital
- Clinic
- Other
Companies covered
- Abbott Laboratories
- Allergan, Inc
- Astellas
- Kissei Pharmaceutical
- Merck & Co.
- Sanofi
- Hainan Selike Pharmaceutical Co., Ltd.
- Hunan Shentaichun Pharmaceutical Co., Ltd.
- China Resources Saike Pharmaceutical Co., Ltd.
- Jiangsu Lianhuan Pharmaceutical Co., Ltd.
- Jiangsu Yongan Pharmaceutical Co., Ltd.
- Kunming Jida Pharmaceutical Co., Ltd.
- Lunan Beite Pharmaceutical Co., Ltd.
- Nanjing Meirui Pharmaceutical Co., Ltd.
- Shandong Langnuo Pharmaceutical Co., Ltd.
- Shanghai Modern Pharmaceutical Co., Ltd.
- Shanghai Abbott Pharmaceutical Co., Ltd.
- Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
- Suzhou Dongrui Pharmaceutical Co., Ltd.
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Zhongshan Kekekang Pharmaceutical Co., Ltd.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Benign Prostatic Hypertrophy Medication Market Size (2021-2032)
- 2.2.2 Global Benign Prostatic Hypertrophy Medication Sales (2021-2032)
- 2.2.3 Global Benign Prostatic Hypertrophy Medication Market Average Price (2021-2032)
- 2.3 Benign Prostatic Hypertrophy Medication by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Terazosin
- 2.3.3 Tamsulosin
- 2.3.4 Silodosin
- 2.3.5 Prusatide
- 2.3.6 Finasteride
- 2.3.7 Aprilite
- 2.3.8 Alfuzosin
- 2.4 Benign Prostatic Hypertrophy Medication by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Benign Prostatic Hypertrophy Medication Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Benign Prostatic Hypertrophy Medication Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Benign Prostatic Hypertrophy Medication Revenue of Manufacturers (2021-2026)
- 3.4 Global Benign Prostatic Hypertrophy Medication Average Price by Manufacturers (2021-2026)
- 3.5 Global Benign Prostatic Hypertrophy Medication Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Benign Prostatic Hypertrophy Medication, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Benign Prostatic Hypertrophy Medication, Product Type & Application
- 3.8 Global Manufacturers of Benign Prostatic Hypertrophy Medication, Established Date
- 3.9 Global Benign Prostatic Hypertrophy Medication Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abbott Laboratories
- 4.1.1 Abbott Laboratories Company Information
- 4.1.2 Abbott Laboratories Business Overview
- 4.1.3 Abbott Laboratories Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abbott Laboratories Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.1.5 Abbott Laboratories Recent Developments
- 4.2 Allergan, Inc
- 4.2.1 Allergan, Inc Company Information
- 4.2.2 Allergan, Inc Business Overview
- 4.2.3 Allergan, Inc Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Allergan, Inc Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.2.5 Allergan, Inc Recent Developments
- 4.3 Astellas
- 4.3.1 Astellas Company Information
- 4.3.2 Astellas Business Overview
- 4.3.3 Astellas Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Astellas Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.3.5 Astellas Recent Developments
- 4.4 Kissei Pharmaceutical
- 4.4.1 Kissei Pharmaceutical Company Information
- 4.4.2 Kissei Pharmaceutical Business Overview
- 4.4.3 Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.4.5 Kissei Pharmaceutical Recent Developments
- 4.5 Merck & Co.
- 4.5.1 Merck & Co. Company Information
- 4.5.2 Merck & Co. Business Overview
- 4.5.3 Merck & Co. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck & Co. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.5.5 Merck & Co. Recent Developments
- 4.6 Sanofi
- 4.6.1 Sanofi Company Information
- 4.6.2 Sanofi Business Overview
- 4.6.3 Sanofi Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sanofi Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.6.5 Sanofi Recent Developments
- 4.7 Hainan Selike Pharmaceutical Co., Ltd.
- 4.7.1 Hainan Selike Pharmaceutical Co., Ltd. Company Information
- 4.7.2 Hainan Selike Pharmaceutical Co., Ltd. Business Overview
- 4.7.3 Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.7.5 Hainan Selike Pharmaceutical Co., Ltd. Recent Developments
- 4.8 Hunan Shentaichun Pharmaceutical Co., Ltd.
- 4.8.1 Hunan Shentaichun Pharmaceutical Co., Ltd. Company Information
- 4.8.2 Hunan Shentaichun Pharmaceutical Co., Ltd. Business Overview
- 4.8.3 Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.8.5 Hunan Shentaichun Pharmaceutical Co., Ltd. Recent Developments
- 4.9 China Resources Saike Pharmaceutical Co., Ltd.
- 4.9.1 China Resources Saike Pharmaceutical Co., Ltd. Company Information
- 4.9.2 China Resources Saike Pharmaceutical Co., Ltd. Business Overview
- 4.9.3 China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.9.5 China Resources Saike Pharmaceutical Co., Ltd. Recent Developments
- 4.10 Jiangsu Lianhuan Pharmaceutical Co., Ltd.
- 4.10.1 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Company Information
- 4.10.2 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Business Overview
- 4.10.3 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.10.5 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Recent Developments
- 4.11 Jiangsu Yongan Pharmaceutical Co., Ltd.
- 4.11.1 Jiangsu Yongan Pharmaceutical Co., Ltd. Company Information
- 4.11.2 Jiangsu Yongan Pharmaceutical Co., Ltd. Business Overview
- 4.11.3 Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.11.5 Jiangsu Yongan Pharmaceutical Co., Ltd. Recent Developments
- 4.12 Kunming Jida Pharmaceutical Co., Ltd.
- 4.12.1 Kunming Jida Pharmaceutical Co., Ltd. Company Information
- 4.12.2 Kunming Jida Pharmaceutical Co., Ltd. Business Overview
- 4.12.3 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.12.5 Kunming Jida Pharmaceutical Co., Ltd. Recent Developments
- 4.13 Lunan Beite Pharmaceutical Co., Ltd.
- 4.13.1 Lunan Beite Pharmaceutical Co., Ltd. Company Information
- 4.13.2 Lunan Beite Pharmaceutical Co., Ltd. Business Overview
- 4.13.3 Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.13.5 Lunan Beite Pharmaceutical Co., Ltd. Recent Developments
- 4.14 Nanjing Meirui Pharmaceutical Co., Ltd.
- 4.14.1 Nanjing Meirui Pharmaceutical Co., Ltd. Company Information
- 4.14.2 Nanjing Meirui Pharmaceutical Co., Ltd. Business Overview
- 4.14.3 Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.14.5 Nanjing Meirui Pharmaceutical Co., Ltd. Recent Developments
- 4.15 Shandong Langnuo Pharmaceutical Co., Ltd.
- 4.15.1 Shandong Langnuo Pharmaceutical Co., Ltd. Company Information
- 4.15.2 Shandong Langnuo Pharmaceutical Co., Ltd. Business Overview
- 4.15.3 Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.15.5 Shandong Langnuo Pharmaceutical Co., Ltd. Recent Developments
- 4.16 Shanghai Modern Pharmaceutical Co., Ltd.
- 4.16.1 Shanghai Modern Pharmaceutical Co., Ltd. Company Information
- 4.16.2 Shanghai Modern Pharmaceutical Co., Ltd. Business Overview
- 4.16.3 Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.16.5 Shanghai Modern Pharmaceutical Co., Ltd. Recent Developments
- 4.17 Shanghai Abbott Pharmaceutical Co., Ltd.
- 4.17.1 Shanghai Abbott Pharmaceutical Co., Ltd. Company Information
- 4.17.2 Shanghai Abbott Pharmaceutical Co., Ltd. Business Overview
- 4.17.3 Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.17.5 Shanghai Abbott Pharmaceutical Co., Ltd. Recent Developments
- 4.18 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
- 4.18.1 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Company Information
- 4.18.2 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Business Overview
- 4.18.3 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.18.5 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Recent Developments
- 4.19 Suzhou Dongrui Pharmaceutical Co., Ltd.
- 4.19.1 Suzhou Dongrui Pharmaceutical Co., Ltd. Company Information
- 4.19.2 Suzhou Dongrui Pharmaceutical Co., Ltd. Business Overview
- 4.19.3 Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.19.5 Suzhou Dongrui Pharmaceutical Co., Ltd. Recent Developments
- 4.20 Zhejiang Huahai Pharmaceutical Co., Ltd.
- 4.20.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
- 4.20.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
- 4.20.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.20.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
- 4.21 Zhongshan Kekekang Pharmaceutical Co., Ltd.
- 4.21.1 Zhongshan Kekekang Pharmaceutical Co., Ltd. Company Information
- 4.21.2 Zhongshan Kekekang Pharmaceutical Co., Ltd. Business Overview
- 4.21.3 Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.21.4 Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 4.21.5 Zhongshan Kekekang Pharmaceutical Co., Ltd. Recent Developments
5 Global Benign Prostatic Hypertrophy Medication Market Scenario by Region
- 5.1 Global Benign Prostatic Hypertrophy Medication Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Benign Prostatic Hypertrophy Medication Sales by Region: 2021-2032
- 5.2.1 Global Benign Prostatic Hypertrophy Medication Sales by Region: 2021-2026
- 5.2.2 Global Benign Prostatic Hypertrophy Medication Sales by Region: 2027-2032
- 5.3 Global Benign Prostatic Hypertrophy Medication Revenue by Region: 2021-2032
- 5.3.1 Global Benign Prostatic Hypertrophy Medication Revenue by Region: 2021-2026
- 5.3.2 Global Benign Prostatic Hypertrophy Medication Revenue by Region: 2027-2032
- 5.4 North America Benign Prostatic Hypertrophy Medication Market Facts & Figures by Country
- 5.4.1 North America Benign Prostatic Hypertrophy Medication Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Benign Prostatic Hypertrophy Medication Sales by Country (2021-2032)
- 5.4.3 North America Benign Prostatic Hypertrophy Medication Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Benign Prostatic Hypertrophy Medication Market Facts & Figures by Country
- 5.5.1 Europe Benign Prostatic Hypertrophy Medication Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Benign Prostatic Hypertrophy Medication Sales by Country (2021-2032)
- 5.5.3 Europe Benign Prostatic Hypertrophy Medication Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Benign Prostatic Hypertrophy Medication Market Facts & Figures by Country
- 5.6.1 Asia Pacific Benign Prostatic Hypertrophy Medication Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Benign Prostatic Hypertrophy Medication Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Benign Prostatic Hypertrophy Medication Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Benign Prostatic Hypertrophy Medication Market Facts & Figures by Country
- 5.7.1 South America Benign Prostatic Hypertrophy Medication Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Benign Prostatic Hypertrophy Medication Sales by Country (2021-2032)
- 5.7.3 South America Benign Prostatic Hypertrophy Medication Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Benign Prostatic Hypertrophy Medication Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Benign Prostatic Hypertrophy Medication Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Benign Prostatic Hypertrophy Medication Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Benign Prostatic Hypertrophy Medication Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Benign Prostatic Hypertrophy Medication Sales by Type (2021-2032)
- 6.1.1 Global Benign Prostatic Hypertrophy Medication Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Benign Prostatic Hypertrophy Medication Sales Market Share by Type (2021-2032)
- 6.2 Global Benign Prostatic Hypertrophy Medication Revenue by Type (2021-2032)
- 6.2.1 Global Benign Prostatic Hypertrophy Medication Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Type (2021-2032)
- 6.3 Global Benign Prostatic Hypertrophy Medication Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Benign Prostatic Hypertrophy Medication Sales by Application (2021-2032)
- 7.1.1 Global Benign Prostatic Hypertrophy Medication Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2021-2032)
- 7.2 Global Benign Prostatic Hypertrophy Medication Revenue by Application (2021-2032)
- 7.2.1 Global Benign Prostatic Hypertrophy Medication Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Application (2021-2032)
- 7.3 Global Benign Prostatic Hypertrophy Medication Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Benign Prostatic Hypertrophy Medication Value Chain Analysis
- 8.1.1 Benign Prostatic Hypertrophy Medication Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Benign Prostatic Hypertrophy Medication Production Mode & Process
- 8.2 Benign Prostatic Hypertrophy Medication Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Benign Prostatic Hypertrophy Medication Distributors
- 8.2.3 Benign Prostatic Hypertrophy Medication Customers
9 Global Benign Prostatic Hypertrophy Medication Analyzing Market Dynamics
- 9.1 Benign Prostatic Hypertrophy Medication Industry Trends
- 9.2 Benign Prostatic Hypertrophy Medication Industry Drivers
- 9.3 Benign Prostatic Hypertrophy Medication Industry Opportunities and Challenges
- 9.4 Benign Prostatic Hypertrophy Medication Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$2,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst